/BMKDF

BMKDF Stock - BioMark Diagnostics Inc.

Q: What is the analyst price target for BMKDF?

Analyst price target information is not currently available for BMKDF.

Q: What is BMKDF's market cap?

Market capitalization information is not currently available for BMKDF.

Healthcare|Medical - Diagnostics & Research|OTC

$0.34+0.00%

+$0.00 (+0.00%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.38

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for BMKDF

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2021

FY2022

FY2023

FY2024

FY2025

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-0.21

52W High$0.37

52W Low$0.12

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$154,216	$163,220	$153,492	$43,933	N/A
Gross Profit	$154,216	$163,220	$153,492	$43,933	$-13,686
Gross Margin	100.0%	100.0%	100.0%	100.0%	N/A
Operating Income	$-1,908,137	$-1,315,677	$-1,731,997	$-1,403,106	$-1,013,856
Net Income	$-1,927,280	$-1,427,385	$-1,842,229	$-1,453,903	$-1,094,190
Net Margin	-1249.7%	-874.5%	-1200.2%	-3309.4%	N/A
EPS	$-0.02	$-0.02	$-0.02	$-0.02	$-0.01

Company Overview

BioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. It has a collaborative research agreement with the Icahn School of Medicine for clinical studies related to early lung cancer diagnosis. The company was incorporated in 2014 and is headquartered in Richmond, Canada. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.

Visit Website

Frequently Asked Questions about BMKDF

What is BMKDF's current stock price?

BioMark Diagnostics Inc. (BMKDF) is currently trading at $0.34 per share. The stock has moved +0.00% today.

What is the analyst price target for BMKDF?

No analyst price targets are currently available for this stock.

What sector is BioMark Diagnostics Inc. in?

BioMark Diagnostics Inc. operates in the Healthcare sector, specifically within the Medical - Diagnostics & Research industry. The company is traded on the OTC exchange.

What is BMKDF's market cap?

BioMark Diagnostics Inc. has a market capitalization of $0.04 billion, making it a small-cap company.

Does BMKDF pay dividends?

No, BioMark Diagnostics Inc. does not currently pay a dividend to shareholders.